Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives
New York, June 13, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Intelligent Bio Solutions Inc.
News Updates
Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology
New York, June 12, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
NEW YORK, May 29, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions
NEW YORK, May 23, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Innovative Fingerprint Drug Screening Solution Showcased at the UK’s Premier Health and Safety Event
NEW YORK, May 17, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024. Cash and
How Does Fingerprint Drug Testing Compare to Urine and Saliva-based Drug Testing?
Traditional drug tests can be intrusive, undignified, and uncomfortable for both test takers and administrators. The Intelligent Fingerprinting Drug Screening
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results
Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024,
Leveraging Fingerprint Testing for Non-Invasive Health Monitoring
Non-invasive health diagnostics are on the rise, and fingerprint testing technology is at the forefront. This article explores the history
Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
NEW YORK, April 11, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
NEW YORK, February 28, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company
Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement
NEW YORK, February 16, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023. Expanded into
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results
Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six months ended December 31, 2023
Fingerprint Drug Test Delivers Quantifiable Benefits for Customers as Adoption in Workplaces Accelerates
Customers identify in-house control, project flexibility, productivity, and cost reductions as key business benefits of fingerprint drug testing
Media
